Hostname: page-component-7479d7b7d-68ccn Total loading time: 0 Render date: 2024-07-11T22:45:11.387Z Has data issue: false hasContentIssue false

P03-354 How Frequently are Atypical Antipsychotics used to Treat OCD in a British Community Mental Health Team?

Published online by Cambridge University Press:  17 April 2020

M. Birtwhistle
Affiliation:
Intensive Care, Bedford Hospital, Bedford, UK
M. Agius
Affiliation:
Academic Department of Psychiatry, University of Cambridge, Luton, UK Psychiatry, Bedfordshire and Luton Partnership Trust, Bedford, UK
R. Zaman
Affiliation:
Psychiatry, Bedfordshire and Luton Partnership Trust, Bedford, UK Academic Department of Psychiatry, University of Cambridge, Cambridge, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

After initial psychological treatment patients with Obsessive Compulsive Disorder are treated with selective serotonin re-uptake inhibitors (SSRIs). Treatment may later be augmented with clomipramine and/or an antipsychotic. This study focuses on the biological treatment received after, or in parallel to, the psychological.

Aim

To collate and evaluate the levels of biological treatment currently received by OCD outpatients in the Bedford east catchment of Bedfordshire and Luton mental health and social care partnership NHS trust.

Objectives

In particular we wished to establish how many of the patients were receiving an atypical antipsychotic as well as maximal SSRIs.

Method

An anonymised database of 45 outpatients with symptoms of OCD was prepared. Treatment groups were identified and the percentage of the cohort occupied by these groups was calculated. The possibilities for increased medication were noted.

Results

Only 7% of patients had one SSRI, at maximum dose, plus clomipramine, plus an antipsychotic, even here the dosing was not maximal. Another 7% had a second SSRI instead of the tricyclic and may benefit from a trial of clomipramine. In the remaining 86% there was further scope for increasing biological therapy.

Discussion

Relatively few of our patients were having maximal SSRI treatment and an antipsychotic, despite guideline recommendations.

Conclusion

There is plenty of leeway for the escalation of patients’ biological therapy. Given the number of patients currently receiving secondary care, an escalation of their treatment should result in better patient health and a subsequent increase in discharges.

Type
Psychopharmacological treatment and biological therapies
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.